The role of focal therapy in the management of localised prostate cancer: A systematic review

European Urology

Volumn 66, Issue 4, 2014, Pages 732-751

  Valerio, Massimo ^a,b,c   Ahmed, Hashim U ^a,b   Emberton, Mark ^a,b   Lawrentschuk, Nathan ^d   Lazzeri, Massimo ^e   Montironi, Rodolfo ^f   Nguyen, Paul L ^g   Trachtenberg, John ^h   Polascik, Thomas J ⁱ  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e SAN RAFFAELE HOSPITAL   (Italy)

^f UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^g HARVARD MEDICAL SCHOOL   (United States)

^h UNIVERSITY OF TORONTO   (Canada)

ⁱ DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Brachytherapy; Cryotherapy; High intensity focused ultrasound; Laser therapy; Photodynamic therapy; Prostate cancer

Indexed keywords

ANTINEOPLASTIC AGENT;

CANCER CONTROL; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CANCER THERAPY; DISEASE FREE SURVIVAL; DOPPLER FLOWMETRY; FOCAL THERAPY; FOLLOW UP; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROSTATE CANCER; RETROSPECTIVE STUDY; REVIEW; SALVAGE THERAPY; SYSTEMATIC REVIEW; TREATMENT FAILURE; TUMOR BIOPSY; AGED; CANCER STAGING; COMPARATIVE STUDY; CRYOTHERAPY; EVIDENCE BASED MEDICINE; HIGH INTENSITY FOCUSED ULTRASOUND; LOW LEVEL LASER THERAPY; MALE; MIDDLE AGED; MORTALITY; PATHOLOGY; PATIENT SELECTION; PHOTOCHEMOTHERAPY; PROCEDURES; PROGNOSIS; PROSTATIC NEOPLASMS; RISK ASSESSMENT; ROLE PLAYING; SURVIVAL; TREATMENT OUTCOME; TUMOR INVASION; BRACHYTHERAPY; CANCER LOCALIZATION; CANCER SPECIFIC SURVIVAL; CRYOABLATION; EXTERNAL BEAM RADIOTHERAPY; INFORMATION RETRIEVAL; INTENTION TO TREAT ANALYSIS; META ANALYSIS; PATIENT RISK; PHOTODYNAMIC THERAPY; POPULATION; PROSPECTIVE STUDY; PROSTATE BIOPSY; PROTON THERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC);

AGED; CRYOTHERAPY; DISEASE-FREE SURVIVAL; EVIDENCE-BASED MEDICINE; HUMANS; LASER THERAPY; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PATIENT SELECTION; PHOTOCHEMOTHERAPY; PROGNOSIS; PROSTATIC NEOPLASMS; RISK ASSESSMENT; ROLE; SURVIVAL ANALYSIS; TREATMENT OUTCOME; ULTRASOUND, HIGH-INTENSITY FOCUSED, TRANSRECTAL;

EID: 84898543801     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2013.05.048     Document Type: Review

References (112)

1. T.J. Wilt, M.K. Brawer, and K.M. Jones et al. Radical prostatectomy versus observation for localized prostate cancer N Engl J Med 367 2012 203 213
2. V. Ficarra, G. Novara, and R.C. Rosen et al. Systematic review and meta-analysis of studies reporting urinary continence recovery after robot-assisted radical prostatectomy Eur Urol 62 2012 405 417
3. V. Ficarra, G. Novara, and T.E. Ahlering et al. Systematic review and meta-analysis of studies reporting potency rates after robot-assisted radical prostatectomy Eur Urol 62 2012 418 430
4. M.J. Resnick, T. Koyama, and K.H. Fan et al. Long-term functional outcomes after treatment for localized prostate cancer N Engl J Med 368 2013 436 445
5. N.C. Sheets, G.H. Goldin, and A.M. Meyer et al. Intensity-modulated radiation therapy, proton therapy, or conformal radiation therapy and morbidity and disease control in localized prostate cancer JAMA 307 2012 1611 1620
6. U. Lindner, J. Trachtenberg, and N. Lawrentschuk Focal therapy in prostate cancer: modalities, findings and future considerations Nat Rev Urol 7 2010 562 571
7. J. De la Rosette, H. Ahmed, and J. Barentsz et al. Focal therapy in prostate cancer-report from a consensus panel J Endourol 24 2010 775 780
8. S. Eggener, G. Salomon, P.T. Scardino, J. De la Rosette, T.J. Polascik, and S. Brewster Focal therapy for prostate cancer: possibilities and limitations Eur Urol 58 2010 57 64
9. H.U. Ahmed, D. Pendse, R. Illing, C. Allen, J.H. van der Meulen, and M. Emberton Will focal therapy become a standard of care for men with localized prostate cancer? Nat Clin Pract Oncol 4 2007 632 642
10. W. Liu, S. Laitinen, and S. Khan et al. Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer Nat Med 15 2009 559 565
11. P. McCulloch, D.G. Altman, and W.B. Campbell et al. No surgical innovation without evaluation: the IDEAL recommendations Lancet 374 2009 1105 1112
12. Oxford Centre for Evidence-based Medicine - levels of evidence (March 2009). Oxford Centre for Evidence-Based Medicine Web Site. http://www.cebm.net/? o=1025. Accessed December 14, 2012.
13. P. McCulloch The IDEAL recommendations and urological innovation World J Urol 29 2011 331 336
14. G. Novara, V. Ficarra, and R.C. Rosen et al. Systematic review and meta-analysis of perioperative outcomes and complications after robot-assisted radical prostatectomy Eur Urol 62 2012 431 452
15. S. Madersbacher, M. Pedevilla, L. Vingers, M. Susani, and M. Marberger Effect of high-intensity focused ultrasound on human prostate cancer in vivo Cancer Res 55 1995 3346 3351
16. A.R. Zlotta, B. Djavan, and C. Matos et al. Percutaneous transperineal radiofrequency ablation of prostate tumour: safety, feasibility and pathological effects on human prostate cancer Br J Urol 81 1998 265 275
17. H.P. Beerlage, S. Thuroff, F.M. Debruyne, C. Chaussy, and J.J. de la Rosette Transrectal high-intensity focused ultrasound using the Ablatherm device in the treatment of localized prostate carcinoma Urology 54 1999 273 277
18. R. Souchon, O. Rouviere, and A. Gelet et al. Visualisation of HIFU lesions using elastography of the human prostate in vivo: preliminary results Ultrasound Med Biol 29 2003 1007 1015
19. C.M. Moore, T.R. Nathan, and W.R. Lees et al. Photodynamic therapy using meso tetra hydroxy phenyl chlorin (mTHPC) in early prostate cancer Lasers Surg Med 38 2006 356 363
20. D.K. Bahn, P. Silverman, F. Lee Sr., R. Badalament, E.D. Bahn, and J.C. Rewcastle Focal prostate cryoablation: initial results show cancer control and potency preservation J Endourol 20 2006 688 692
21. G. Onik, D. Vaughan, R. Lotenfoe, M. Dineen, and J. Brady "Male lumpectomy": focal therapy for prostate cancer using cryoablation Urology 70 Suppl 2007 16 21
22. D.S. Ellis, T.B. Manny Jr., and J.C. Rewcastle Focal cryosurgery followed by penile rehabilitation as primary treatment for localized prostate cancer: initial results Urology 70 Suppl 2007 9 15
23. S. Muto, T. Yoshii, K. Saito, Y. Kamiyama, H. Ide, and S. Horie Focal therapy with high-intensity-focused ultrasound in the treatment of localized prostate cancer Jpn J Clin Oncol 38 2008 192 199
24. F.J. Murat, A. Cherasse, and L. Poissonier et al. Focal therapy of prostate cancer (PCa) with HIFU: influence on erectile dysfunction (ED) Eur Urol Suppl 8 2009 334
25. U. Lindner, R.A. Weersink, and M.A. Haider et al. Image guided photothermal focal therapy for localized prostate cancer: phase I trial J Urol 182 2009 1371 1377
26. U. Lindner, N. Lawrentschuk, and R.A. Weersink et al. Focal laser ablation for prostate cancer followed by radical prostatectomy: validation of focal therapy and imaging accuracy Eur Urol 57 2010 1111 1114
27. O. Raz, M.A. Haider, and S.R.H. Davidson et al. Real-time magnetic resonance imaging-guided focal laser therapy in patients with low-risk prostate cancer Eur Urol 58 2010 173 177
28. M.D. Truesdale, P.J. Cheetham, and G.W. Hruby et al. An evaluation of patient selection criteria on predicting progression-free survival after primary focal unilateral nerve-sparing cryoablation for prostate cancer: recommendations for follow up Cancer J 16 2010 544 549
29. El Fegoun AB, Barret E, Prapotnich D, et al. Focal therapy with high-intensity focused ultrasound for prostate cancer in the elderly. A feasibility study with 10 years follow-up. Int Braz J Urol 2011;37:213-9; discussion 220-2.
30. H.U. Ahmed, A. Freeman, and A. Kirkham et al. Focal therapy for localized prostate cancer: a phase I/II trial J Urol 185 2011 1246 1254
31. J.F. Ward, and J.S. Jones Focal cryotherapy for localized prostate cancer: a report from the national Cryo On-Line Database (COLD) Registry BJU Int 109 2012 1648 1654
32. K.J. Tay, C. Cheng, and J.W. Kwek et al. Initial experience with MRgFUS focal therapy for low-risk prostate cancer J Endourol 25 2011 A99 A100
33. R. Chopra, A. Colquhoun, and M. Burtnyk et al. MR imaging-controlled transurethral ultrasound therapy for conformal treatment of prostate tissue: initial feasibility in humans Radiology 265 2012 303 313
34. D. Bahn, A.L. de Castro Abreu, and I.S. Gill et al. Focal cryotherapy for clinically unilateral, low-intermediate risk prostate cancer in 73 men with a median follow-up of 3.7 years Eur Urol 62 2012 55 63
35. H.U. Ahmed, R.G. Hindley, and L. Dickinson et al. Focal therapy for localised unifocal and multifocal prostate cancer: a prospective development study Lancet Oncol 13 2012 622 632
36. L. Dickinson, H.U. Ahmed, and N. McCartan et al. Medium term outcomes following primary focal therapy using HIFU for localised prostate cancer BJU Int 109 Suppl S7 2012 6
37. P.L. Nguyen, M.H. Chen, and Y. Zhang et al. Updated results of magnetic resonance imaging guided partial prostate brachytherapy for favorable risk prostate cancer: implications for focal therapy J Urol 188 2012 1151 1156
38. A. Napoli, M. Anzidei, and C. De Nunzio et al. Real-time magnetic resonance-guided high-intensity focused ultrasound focal therapy for localised prostate cancer: preliminary experience Eur Urol 63 2013 395 398
39. E. Barret, Y. Ahallal, and R. Sanchez-Salas et al. Morbidity of focal therapy in the treatment of localized prostate cancer Eur Urol 63 2013 618 622
40. S.F. Shariat, G. Raptidis, M. Masatoschi, F. Bergamaschi, and K.M. Slawin Pilot study of radiofrequency interstitial tumor ablation (RITA) for the treatment of radio-recurrent prostate cancer Prostate 65 2005 260 267
41. P.L. Nguyen, M.H. Chen, and A.V. D'Amico et al. Magnetic resonance image-guided salvage brachytherapy after radiation in select men who initially presented with favorable-risk prostate cancer: a prospective phase 2 study Cancer 110 2007 1485 1492
42. M.L. Eisenberg, and K. Shinohara Partial salvage cryoablation of the prostate for recurrent prostate cancer after radiotherapy failure Urology 72 2008 1315 1318
43. H.U. Ahmed, P. Cathcart, and N. McCartan et al. Focal salvage therapy for localized prostate cancer recurrence after external beam radiotherapy: a pilot study Cancer 118 2012 4148 4155
44. A.L.D.C. Abreu, H. Ahmadi, and S. Leslie et al. Salvage focal versus salvage total cryoablation for radio-recurrent prostate cancer: cancer control and harm-reduction J Endourol 26 2011 A208
45. Eggener S. A pilot study to evaluate magnetic resonance thermal image-guided laser-induced interstitial thermal therapy for focal ablation of prostate cancer [ClinicalTrials.gov identifier NCT01192438 ]. Clinicaltrials.gov Web site. http://clinicaltrials-lhc.nlm.nih.gov/ct2/show/study/NCT01192438? view=results.
46. Taneja S. A prospective, multicenter phase I/II safety and tolerability study of unilateral vascular-targeted photodynamic therapy using WST11 in patients with localized prostate cancer [ClinicalTrials.gov identifier NCT00946881 ]. Clinicaltrials.gov Web site. http://clinicaltrials.gov/show/ NCT00946881.
47. Emberton M. Vascular-targeted photodynamic therapy using WST11 in patients with localized prostate cancer [ClinicalTrials.gov identifier NCT00975429 ]. Clinicaltrials.gov Web site. http://clinicaltrials.gov/ct2/show/ NCT00975429?term=NCT00975429&rank=1.
48. Emberton M. A European randomised phase 3 study to assess the efficacy and safety of TOOKAD® Soluble for localised prostate cancer compared to active surveillance [ClinicalTrials.gov identifier NCT01310894 ]. ClinicalTrials.gov Web site. http://clinicaltrials.gov/show/NCT01310894.
49. Emberton M. A multi-center prospective single arm intervention trial evaluating focal therapy using high intensity focused ultrasound (Sonablate 500) for localized prostate cancer [ClinicalTrials.gov identifier NCT01194648 ]. ClinicalTrials.gov Web site. http://clinicaltrials.gov/ct2/show/NCT01194648? term=NCT01194648&rank=1.
50. Ahmed HU. An evaluation of lesion control using focal ablation with high intensity focused ultrasound in the treatment of non-metastatic progressive prostate cancer [ClinicalTrials.gov identifier NCT00987675 ]. ClinicalTrials.gov Web site. http://clinicaltrials.gov/ct2/show/NCT00987675?term= NCT00987675&rank=1.
51. Guazzoni G. Focal therapy for organ confined prostate cancer: an investigative prospective pilot study [ClinicalTrials.gov identifier NCT00928603 ]. ClinicalTrials.gov Web site. http://clinicaltrials.gov/ct2/show/NCT00928603? term=NCT00928603&rank=1.
52. Napoli A. Focal therapy with magnetic resonance guided focused ultrasound treatment of locally non-advanced prostate cancer: phase 1 study [ClinicalTrials.gov identifier NCT01522118 ]. ClinicalTrials.gov Web site. http://clinicaltrials.gov/ct2/show/NCT01522118?term=NCT01522118&rank=1.
53. Zelefsky M. Phase II study assessing the potential for reduced toxicity using focal brachytherapy early stage, low volume in prostate cancer [ClinicalTrials.gov identifier NCT01354951 ]. ClinicalTrials.gov Web site. http://clinicaltrials.gov/ct2/show/NCT01354951?term=NCT01354951&rank=1.
54. Ward JF. Regional cryoablation for localized adenocarcinoma of the prostate [ClinicalTrials.gov identifier NCT00877682 ]. ClinicalTrials.gov Web site. http://clinicaltrials.gov/ct2/show/NCT00877682?term=NCT00877682&rank= 1.
55. Eastham J. A phase II study of focal cryoablation in low-risk prostate cancer [ClinicalTrials.gov identifier NCT00774436 ]. ClinicalTrials.gov Web site. http://clinicaltrials.gov/ct2/show/NCT00774436?term=NCT00774436&rank= 1.
56. Emberton M. A prospective development study evaluating focal therapy using irreversible electroporation (Nanoknife®) in men with localised prostate cancer [ClinicalTrials.gov identifier NCT01726894 ]. ClinicalTrials.gov Web site. http://clinicaltrials.gov/ct2/show/NCT01726894?term= NCT01726894&rank=1.
57. Chung H. Pilot study of focal salvage HDR prostate brachytherapy [ClinicalTrials.gov identifier NCT01583920 ]. ClinicalTrials.gov Web site. http://clinicaltrials.gov/ct2/show/NCT01583920?term=NCT01583920&rank=1.
58. S.E. Eggener, P.T. Scardino, and P.R. Carroll et al. Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities J Urol 178 2007 2260 2267
59. S. Langley, H.U. Ahmed, and B. Al-Qaisieh et al. Report of a consensus meeting on focal low dose rate brachytherapy for prostate cancer BJU Int 109 Suppl 1 2012 7 16
60. H.U. Ahmed, O. Akin, and J.A. Coleman et al. Transatlantic consensus group on active surveillance and focal therapy for prostate cancer BJU Int 109 2012 1636 1647
61. Bostwick DG, Waters DJ, Farley ER, et al. Group consensus reports from the Consensus Conference on Focal Treatment of Prostatic Carcinoma, Celebration, Florida, February 24, 2006. Urology 2007; 70(Suppl):42-4.
62. J.M. Mayes, V. Mouraviev, L. Sun, M. Tsivian, J.F. Madden, and T.J. Polascik Can the conventional sextant prostate biopsy accurately predict unilateral prostate cancer in low-risk, localized, prostate cancer? Urol Oncol 29 2011 166 170
63. K.D. Berg, B.G. Toft, M.A. Roder, K. Brasso, B. Vainer, and P. Iversen Is it possible to predict low-volume and insignificant prostate cancer by core needle biopsies? APMIS 121 2013 257 265
64. M. Sinnott, S.M. Falzarano, and A.V. Hernandez et al. Discrepancy in prostate cancer localization between biopsy and prostatectomy specimens in patients with unilateral positive biopsy: implications for focal therapy Prostate 72 2012 1179 1186
65. A. Gallina, C. Maccagnano, and N. Suardi et al. Unilateral positive biopsies in low risk prostate cancer patients diagnosed with extended transrectal ultrasound-guided biopsy schemes do not predict unilateral prostate cancer at radical prostatectomy BJU Int 110 2012 E64 E68
66. S.L. Washington, M. Bonham, J.M. Whitson, J.E. Cowan, and P.R. Carroll Transrectal ultrasonography-guided biopsy does not reliably identify dominant cancer location in men with low-risk prostate cancer BJU Int 110 2012 50 55
67. B. Katz, M. Srougi, and M. Dall'Oglio et al. Are we able to correctly identify prostate cancer patients who could be adequately treated by focal therapy? Urol Oncol 30 2012 794 797
68. M. Tsivian, D.M. Moreira, and L. Sun et al. Biopsy accuracy in identifying unilateral prostate cancer depends on prostate weight Urol Oncol 30 2012 21 25
69. M. Tsivian, M. Kimura, L. Sun, V. Mouraviev, J.M. Mayes, and T.J. Polascik Predicting unilateral prostate cancer on routine diagnostic biopsy: sextant vs extended BJU Int 105 2010 1089 1092
70. T.J. Polascik, J.M. Mayes, and F.R. Schroeck et al. Patient selection for hemiablative focal therapy of prostate cancer: variables predictive of tumor unilaterality based upon radical prostatectomy Cancer 115 2009 2104 2110
71. A. Losa, G.M. Gadda, and M. Lazzeri et al. Complications and quality of life after template-assisted transperineal prostate biopsy in patients eligible for focal therapy Urology 81 2013 1291 1296
72. E.D. Crawford, K.O. Rove, and A.B. Barqawi et al. Clinical-pathologic correlation between transperineal mapping biopsies of the prostate and three-dimensional reconstruction of prostatectomy specimens Prostate 73 2013 778 787
73. J.A. Long, N. Hungr, and M. Baumann et al. Development of a novel robot for transperineal needle based interventions: focal therapy, brachytherapy and prostate biopsies J Urol 188 2012 1369 1374
74. T. Hossack, M.I. Patel, and A. Huo et al. Location and pathological characteristics of cancers in radical prostatectomy specimens identified by transperineal biopsy compared to transrectal biopsy J Urol 188 2012 781 785
75. A.S. Huo, T. Hossack, and J.L. Symons et al. Accuracy of primary systematic template guided transperineal biopsy of the prostate for locating prostate cancer: a comparison with radical prostatectomy specimens J Urol 187 2012 2044 2049
76. Y. Hu, H.U. Ahmed, and T. Carter et al. A biopsy simulation study to assess the accuracy of several transrectal ultrasonography (TRUS)-biopsy strategies compared with template prostate mapping biopsies in patients who have undergone radical prostatectomy BJU Int 110 2012 812 820
77. H.U. Ahmed, Y. Hu, and T. Carter et al. Characterizing clinically significant prostate cancer using template prostate mapping biopsy J Urol 186 2011 458 464
78. A.B. Barqawi, K.O. Rove, S. Gholizadeh, C.I. O'Donnell, H. Koul, and E.D. Crawford The role of 3-dimensional mapping biopsy in decision making for treatment of apparent early stage prostate cancer J Urol 186 2011 80 85
79. G. Onik, M. Miessau, and D.G. Bostwick Three-dimensional prostate mapping biopsy has a potentially significant impact on prostate cancer management J Clin Oncol 27 2009 4321 4326
80. P. Puech, E. Potiron, and L. Lemaitre et al. Dynamic contrast-enhanced- magnetic resonance imaging evaluation of intraprostatic prostate cancer: correlation with radical prostatectomy specimens Urology 74 2009 1094 1099
81. A. Villers, P. Puech, D. Mouton, X. Leroy, C. Ballereau, and L. Lemaitre Dynamic contrast enhanced, pelvic phased array magnetic resonance imaging of localized prostate cancer for predicting tumor volume: correlation with radical prostatectomy findings J Urol 176 2006 2432 2437
82. L.A. Simmons, P. Autier, and F. Zat'ura et al. Detection, localisation and characterisation of prostate cancer by prostate HistoScanning(™) BJU Int 110 2012 28 35
83. Y. Zhu, Y. Chen, and T. Qi et al. Prostate cancer detection with real-time elastography using a bi-plane transducer: comparison with step section radical prostatectomy pathology World J Urol 32 2014 329 333
84. J.L. Gulley, M. Emberton, J. Kurhanewicz, and P. Choyke Progress in prostate cancer imaging Urol Oncol 30 2012 938 939
85. M. Smeenge, J.J. de la Rosette, and H. Wijkstra Current status of transrectal ultrasound techniques in prostate cancer Curr Opin Urol 22 2012 297 302
86. P.A. Humphrey Complete histologic serial sectioning of a prostate gland with adenocarcinoma Am J Surg Pathol 17 1993 468 472
87. M. Piersanti, S. Ezzat, and S.L. Asa Controversies in papillary microcarcinoma of the thyroid Endocr Pathol 14 2003 183 191
88. C.J. Allegra, D.R. Aberle, and P. Ganschow et al. National Institutes of Health State-of-the-Science Conference statement: diagnosis and management of ductal carcinoma in situ September 22-24, 2009 J Natl Cancer Inst 102 2010 161 169
89. J.A. Graversen, A.C. Mues, A. Perez-Lanzac de Lorca, and J. Landman Active surveillance of renal cortical neoplasms: a contemporary review Postgrad Med 123 2011 105 113
90. T.D. Jones, and L. Cheng Papillary urothelial neoplasm of low malignant potential: evolving terminology and concepts J Urol 175 2006 1995 2003
91. P. Nevoux, A. Ouzzane, and H.U. Ahmed et al. Quantitative tissue analyses of prostate cancer foci in an unselected cystoprostatectomy series BJU Int 110 2012 517 523
92. J.W. Catto, M.C. Robinson, and P.C. Albertsen et al. Suitability of PSA-detected localised prostate cancers for focal therapy: experience from the ProtecT study Br J Cancer 105 2011 931 937
93. V. Mouraviev, A. Villers, D.G. Bostwick, T.M. Wheeler, R. Montironi, and T.J. Polascik Understanding the pathological features of focality, grade and tumour volume of early-stage prostate cancer as a foundation for parenchyma-sparing prostate cancer therapies: active surveillance and focal targeted therapy BJU Int 108 2011 1074 1085
94. T.A. Masterson, L. Cheng, and M.O. Koch Pathological characterization of unifocal prostate cancers in whole-mount radical prostatectomy specimens BJU Int 107 2011 1587 1591
95. T.J. Polascik, J.M. Mayes, L. Sun, J.F. Madden, J.W. Moul, and V. Mouraviev Pathologic stage T2a and T2b prostate cancer in the recent prostate-specific antigen era: implications for unilateral ablative therapy Prostate 68 2008 1380 1386
96. V. Mouraviev, J.M. Mayes, L. Sun, J.F. Madden, J.W. Moul, and T.J. Polascik Prostate cancer laterality as a rationale of focal ablative therapy for the treatment of clinically localized prostate cancer Cancer 110 2007 906 910
97. V. Mouraviev, J.M. Mayes, J.F. Madden, L. Sun, and T.J. Polascik Analysis of laterality and percentage of tumor involvement in 1386 prostatectomized specimens for selection of unilateral focal cryotherapy Technol Cancer Res Treat 6 2007 91 95
98. M. Karavitakis, H.U. Ahmed, P.D. Abel, S. Hazell, and M.H. Winkler Anatomically versus biologically unifocal prostate cancer: a pathological evaluation in the context of focal therapy Ther Adv Urol 4 2012 155 160
99. J.F. Ward, H. Nakanishi, L. Pisters, R.J. Babaian, and P. Troncoso Cancer ablation with regional templates applied to prostatectomy specimens from men who were eligible for focal therapy BJU Int 104 2009 490 497
100. S.R. Bott, H.U. Ahmed, R.G. Hindley, A. Abdul-Rahman, A. Freeman, and M. Emberton The index lesion and focal therapy: an analysis of the pathological characteristics of prostate cancer BJU Int 106 2010 1607 1611
101. R. Mazzucchelli, M. Scarpelli, and L. Cheng et al. Pathology of prostate cancer and focal therapy ('male lumpectomy') Anticancer Res 29 2009 5155 5161
102. F. Algaba, and R. Montironi Impact of prostate cancer multifocality on its biology and treatment J Endourol 24 2010 799 804
103. H.U. Ahmed The index lesion and the origin of prostate cancer N Engl J Med 361 2009 1704 1706
104. D. Lin, J. Bayani, and Y. Wang et al. Development of metastatic and non-metastatic tumor lines from a patient's prostate cancer specimen - identification of a small subpopulation with metastatic potential in the primary tumor Prostate 70 2010 1636 1644
105. A.M. Wise, T.A. Stamey, J.E. McNeal, and J.L. Clayton Morphologic and clinical significance of multifocal prostate cancers in radical prostatectomy specimens Urology 60 2002 264 269
106. T.A. Stamey, F.S. Freiha, J.E. McNeal, E.A. Redwine, A.S. Whittemore, and H.P. Schmid Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer Cancer 71 Suppl 1993 933 938
107. T. Wolters, M.J. Roobol, and P.J. van Leeuwen et al. A critical analysis of the tumor volume threshold for clinically insignificant prostate cancer using a data set of a randomized screening trial J Urol 185 2011 121 125
108. T.H. Van der Kwast The trade-off between sensitivity and specificity of clinical protocols for identification of insignificant prostate cancer Eur Urol 62 2012 469 471
109. C.S. Grasso, Y.M. Wu, and D.R. Robinson et al. The mutational landscape of lethal castration-resistant prostate cancer Nature 487 2012 239 243
110. P.A. Ganz, J.M. Barry, and W. Burke et al. NIH State-of-the-Science Conference Statement: role of active surveillance in the management of men with localized prostate cancer NIH Consens State Sci Statements 28 2011 1 27
111. M. Roach III, G. Hanks, and H. Thames Jr. et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference Int J Radiat Oncol Biol Phys 65 2006 965 974
112. R. Ganzer, C.N. Robertson, and J.F. Ward et al. Correlation of prostate-specific antigen nadir and biochemical failure after high-intensity focused ultrasound of localized prostate cancer based on the Stuttgart failure criteria - analysis from the @-Registry BJU Int 108 2011 E196 E201